Kampanjeplan MiNK Therapeutics, Inc.
Avansert tidsplan
Enkel graf
Om selskapet
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
EBITDA |
-0.0222 |
EV/EBITDA |
-1.19 |
IPO date |
2021-10-15 |
ISIN |
US6036931029 |
Industry |
Biotechnology |
P/BV |
6.28 |
P/S |
0.0288 |
Sector |
Health Care |
Валюта |
usd |
Валюта отчета |
usd |
Выручка |
0.00069 |
Сайт |
https://minktherapeutics.com
|
Цена ао |
0.938 |
Число акций ао |
0.03436 млрд |
Prisendring per dag: |
+8.92% (0.5279) |
Prisendring per uke: |
+9.73% (0.524) |
Prisendring per måned: |
-20.15% (0.7201) |
Prisendring over 3 måneder: |
-23.57% (0.7523) |
Prisendring over seks måneder: |
-35.39% (0.89) |
Prisendring per år: |
-46.26% (1.07) |
Prisendring over 3 år: |
-87.05% (4.44) |
Prisendring over 5 år: |
0% (0.575) |
Prisendring over 10 år: |
0% (0.575) |
Prisendring siden begynnelsen av året: |
+9.73% (0.524) |
|
Undervurdering
Navn |
Betydning |
Karakter |
P/S |
0.0222 |
10 |
P/BV |
-1.94 |
0 |
P/E |
0 |
0 |
EV/EBITDA |
-1.4 |
0 |
Total: |
|
5 |
|
Effektivitet
Navn |
Betydning |
Karakter |
ROA, % |
-493.33 |
0 |
ROE, % |
124.38 |
10 |
Total: |
|
3.33 |
|
|
Utbytte
Navn |
Betydning |
Karakter |
Div yield, % |
0 |
0 |
DSI |
0 |
0 |
Total: |
|
0 |
|
Plikt
Navn |
Betydning |
Karakter |
Debt/EBITDA |
0 |
10 |
Total: |
|
10 |
|
Vekstimpuls
Navn |
Betydning |
Karakter |
Lønnsomhet Revenue, % |
391891.74 |
10 |
Lønnsomhet Ebitda, % |
0.2398 |
1 |
Lønnsomhet EPS, % |
-35.29 |
0 |
Total: |
|
2.4 |
|
Veileder |
Stillingstittel |
Betaling |
Fødselsår |
Dr. Garo H. Armen Ph.D. |
Executive Chairman |
N/A |
1953 (72 år) |
Dr. Jennifer S. Buell Ph.D. |
President, CEO & Director |
916.75k |
1975 (50 år) |
Dr. Marcus Antonius van Dijk Ph.D. |
Chief Scientific Officer |
458.28k |
1962 (63 år) |
Ms. Christine M. Klaskin |
Treasurer |
29.62k |
1966 (59 år) |
Joy Zhou Ph.D. |
Vice President & Head of CMC |
N/A |
|
Mr. Robert Foster |
Director Of Legal & Business Affairs |
|
|